Janney Montgomery Scott
IOVA icon

Janney Montgomery Scott’s Iovance Biotherapeutics IOVA Stock Holding History

Janney Montgomery Scott’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25,755
Closed -$86K – 2763
2025
Q1 		$86K Sell
25,755
-2,439
-9% -$12.6K ﹤0.01% 2619
2024
Q4 		$209K Sell
28,194
-1,670
-6% -$15.5K ﹤0.01% 2528
2024
Q3 		$280K Sell
29,864
-3,083
-9% -$29.2K ﹤0.01% 2328
2024
Q2 		$264K Buy
+32,947
New +$353K ﹤0.01% 2283

Other funds holding IOVA

MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Janney Montgomery Scott's IOVA Position: Q2 2025 in Review

Janney Montgomery Scott sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 25,755 shares — an estimated $86K sold.

Janney Montgomery Scott first reported a position in IOVA in Q2 2024 and held it in 4 quarters. The position peaked at $280K in Q3 2024. 254 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • Janney Montgomery Scott reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Janney Montgomery Scott sold 25,755 Iovance Biotherapeutics shares in Q2 2025, an estimated $86K.
  • Janney Montgomery Scott first reported a position in Iovance Biotherapeutics in Q2 2024 and held it in 4 quarters.
  • Janney Montgomery Scott's Iovance Biotherapeutics position peaked at $280K in Q3 2024.
  • 254 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on Janney Montgomery Scott's 13F filing for Q2 2025, filed 17 Jul 2025.